Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: A retrospective study

被引:2
作者
Tyagi, Kanika [1 ]
Madan, Swati [1 ,2 ]
Bhatt, Surya Prakash [2 ,3 ,4 ]
Ansari, Irshad Ahmad [1 ,2 ]
Dutta, Koel [1 ]
Misra, Anoop [1 ,2 ,3 ]
机构
[1] Fortis C DOC Ctr Excellence Diabet Metab Dis & End, New Delhi, India
[2] Natl Diabet Obes & Cholesterol Fdn N DOC, New Delhi, India
[3] Diabet Fdn India DFI, New Delhi, India
[4] All India Inst Med Sci AIIMS, Dept Pulm Crit Care & Sleep Med, New Delhi, India
关键词
SGLT2; inhibitors; Type; 2; diabetes; NAFLD; Hepatic fibrosis; Asian Indians; FATTY LIVER-DISEASE; TRANSIENT ELASTOGRAPHY; STEATOSIS; BIOPSY;
D O I
10.1016/j.clnesp.2023.07.013
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to decrease hepatic transaminases, steatosis, and in some studies, hepatic fibrosis. However, the safety and efficacy of SGLT2i has not been tested in patients who have moderate to severe hepatic fibrosis. Methods: In a retrospective study of sixty patients with moderate to severe hepatic fibrosis (kPa estimated by Fibroscan > 10), SGLT2i were prescribed on top of other oral anti-hyperglycemic medications. The safety and efficacy of SGLT2i were evaluated. Using the Fibroscan, CAP scores (decibel/meter), and liver stiffness measurement (LSM) (kPa, kilopascals) were examined before and after treatment. Results: The mean age of the T2DM patients was 54.7 & PLUSMN; 10.3 years, and the mean duration of T2DM was 8.3 & PLUSMN; 7.1 years. SGLT2i were given from 3 to 36 months. After treatment, a decrease in glycated hemoglobin (HbA1c), and hepatic transaminases (SGOT and SGPT) was recorded. Upon follow up, CAP and kPa scores decreased significantly. Importantly, no adverse drug reaction, such as balanoposthitis, vulvovaginitis, urosepsis, and postural drop in blood pressure, were reported in any patient. Conclusion: In this retrospective cohort study, patient with T2DM and moderate to severe hepatic fibrosis, use of SGLT2i is safe with respect to common adverse effects & may have contributed to improved hepatic profile. & COPY; 2023 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:305 / 310
页数:6
相关论文
共 18 条
  • [1] Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests?
    Afdhal, NH
    [J]. HEPATOLOGY, 2003, 37 (05) : 972 - 974
  • [2] Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study
    Akuta, Norio
    Kawamura, Yusuke
    Fujiyama, Shunichiro
    Saito, Satoshi
    Muraishi, Nozomu
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Arase, Yasuji
    Ikeda, Kenji
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Kumada, Hiromitsu
    [J]. HEPATOLOGY COMMUNICATIONS, 2022, 6 (09) : 2286 - 2297
  • [3] SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
    Akuta, Norio
    Kawamura, Yusuke
    Fujiyama, Shunichiro
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    [J]. INTERNAL MEDICINE, 2020, 59 (16) : 1931 - 1937
  • [4] Diabetes risk prediction model for non-obese Asian Indians residing in North India using cut-off values for pancreatic and intra-abdominal fat volume and liver span
    Anoop, Shajith
    Misra, Anoop
    Mani, Kalaivani
    Pandey, Ravindra Mohan
    Gulati, Seema
    [J]. JOURNAL OF DIABETES, 2016, 8 (05) : 729 - 731
  • [5] Bajaj S, 2009, INDIAN J MED RES, V129, P285
  • [6] Practices of liver biopsy in France: Results of a prospective nationwide survey
    Cadranel, JF
    Rufat, P
    Degos, F
    [J]. HEPATOLOGY, 2000, 32 (03) : 477 - 481
  • [7] Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease
    Duseja, Ajay
    Singh, Shivaram P.
    Mehta, Manu
    Shalimar
    Venkataraman, Jayanthi
    Mehta, Varun
    Devadas, Krishnadas
    Kar, Sanjib K.
    Goyal, Omesh
    Nagral, Aabha
    Saigal, Sanjiv
    Nijhawan, Sandeep
    Praharaj, Dibyalochan
    Shukla, Akash
    Sharma, Brij
    Narayanasamy, K.
    Kumar, Pramod
    Rao, Padaki Nagaraja
    Arora, Anil
    Mehta, Rajiv
    Asati, Pankaj
    Ranjan, Piyush
    Koshy, Abraham
    Alam, Seema
    Mukewar, Shrikant
    Mukewar, Saurabh
    Mohan Prasad, V. G.
    Rastogi, Mukul
    Sanyal, Arun J.
    [J]. METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (03) : 166 - 173
  • [8] SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
    Dwinata, Michael
    Putera, David Dwi
    Hasan, Irsan
    Raharjo, Monica
    [J]. CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2020, 6 (04) : 339 - 346
  • [9] Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India
    Ghosh, Amerta
    Dutta, Koel
    Bhatt, Surya Prakash
    Gupta, Ritesh
    Tyagi, Kanika
    Ansari, Irshad Ahmad
    Venugopal, Vasantha Kumar
    Mahajan, Harsh
    Pandey, Ravindra Mohan
    Pandey, Shivam
    Misra, Anoop
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (06) : E2267 - E2275
  • [10] High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus
    Gupta, Aanchal
    Anoop, Shajith
    Ansari, Irshad Ahmad
    Prakash, Satya
    Misra, Anoop
    [J]. CLINICAL NUTRITION ESPEN, 2021, 46 : 519 - 526